Nuvo Research (Dimethaid Research) signs license agreement with Ranbaxy Laboratories
RBXLF | Quote | Chart | News | PowerRating -- Dimethaid GmbH, a Germany-based subsidiary of Nuvo Research, Inc., has entered into an exclusive license agreement with Ranbaxy Laboratories Limited, for the supply and distribution of Oxoferin(TM) in Malaysia, Cambodia, Philippines, Vietnam, Myanmar, and Singapore.
Both the India-based Ranbaxy and Canada-based Nuvo Research are engaged in pharmaceutical business.
Under the terms of the agreement, Nuvo Research will manufacture and supply Oxoferin(TM) to Ranbaxy. Ranbaxy will be responsible for obtaining regulatory approval in Malaysia, Cambodia, Philippines, Vietnam, Myanmar, and Singapore, and has committed to minimum annual purchase quantities once approved.
Deal Type Partnership
Sub-Category Acquisition of Rights,Distribution,Supply
Deal Status Announced: 2009-11-11
Deal Participants
Partner 1 (Company) Ranbaxy Laboratories Limited
Partner 2 (Company) Nuvo Research, Inc. (formerly Dimethaid Research, Inc.)
Partner 3 (Company) Dimethaid GmbH
For full details on (RBXLF) RBXLF. (RBXLF) has Short Term PowerRatings at TradingMarkets. Details on (RBXLF) Short Term PowerRatings is available at This Link.
For full details on (NRIFF) NRIFF. (NRIFF) has Short Term PowerRatings at TradingMarkets. Details on (NRIFF) Short Term PowerRatings is available at This Link.
- Nuvo Research completes redemption of 5% convertible debentures - 03/17/10
- Ranbaxy signs agreement with Takeda for diabetes drug - 03/17/10
- Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial - 03/15/10
- Ranbaxy Announces Settlement of Actos(R) (Pioglitazone Hydrochloride) Patent Litigation - 03/15/10
- INDIA'S RANBAXY LABS EYES US$3 BLN TURNOVER BY 2012 - 03/14/10
- More News >>


